Cargando…
Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure
Adenosine A(1) receptors (A(1)R) are a potential target for cardiac injury treatment due to their cardioprotective/antihypertrophic actions, but drug development has been hampered by on-target side effects such as bradycardia and altered renal hemodynamics. Biased agonism has emerged as an attractiv...
Autores principales: | Rueda, Patricia, Merlin, Jon, Chimenti, Stefano, Feletou, Michel, Paysant, Jerome, White, Paul J., Christopoulos, Arthur, Sexton, Patrick M., Summers, Roger J., Charman, William N., May, Lauren T., Langmead, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991592/ https://www.ncbi.nlm.nih.gov/pubmed/33776771 http://dx.doi.org/10.3389/fphar.2021.628060 |
Ejemplares similares
-
Structural Basis for Binding of Allosteric Drug Leads in the Adenosine A(1) Receptor
por: Miao, Yinglong, et al.
Publicado: (2018) -
Agonist-bound adenosine A(2A) receptor structures reveal common features of GPCR activation
por: Lebon, Guillaume, et al.
Publicado: (2011) -
Correspondence: Reply to ‘Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injury’
por: Qin, Cheng Xue, et al.
Publicado: (2018) -
Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants
por: Rueda, Patricia, et al.
Publicado: (2016) -
Deletion of GPR21 improves glucose homeostasis and inhibits the CCL2-CCR2 axis by divergent mechanisms
por: Riddy, Darren M, et al.
Publicado: (2021)